Amendment no. 1

No.: - PMBI/DRUG/RC-191/2022

Subject: - Tender No. PMBI/DRUG/RC-191/2022 dated 09/02/2022 for supply of Drugs to PMBI.

Reference: - Pre-Bid Meeting held on 17/02/2022 at 11:00 AM in the premises of PMBI.

Pharmaceuticals and Medical Devices Bureau of India (PMBI) has invited e-Bids from the interested parties for "e- Tender for Supply of Drugs for the year 2022 - 2024", vide Notice Inviting e-Tender No.- **PMBI/DRUG/RC-191/2022**. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website of Central Public Procurement Portal; www.eprocure.gov.in and BPPI Website; www.janaushadhi.gov.in.

After considering the suggestions/queries received from the prospective bidders on or before Pre-Bid meeting, the clarifications/amendments in respect to the tender document and specification of the tendered items have been made as per below Part-A respectively. All other technical specifications, terms, and conditions along with the tender schedule as mentioned in tender document shall remain unamended.

The following amendment in Tender Document is hereby authorized: -

Part- A

~					
Sr.	Tender	Drug Code and Generic name	Query/Suggestions	Tender	Amendment
No.	Clause/			condition/requirement	
	Reference			-	
1	Annexure-XII	DC – 2148 Atorvastatin Tablets	One of the prospective bidders has	Unit Size – 10's	Tender condition prevails.
	Clause 18(M)	IP 80mg	requested to amend the unit size to 7's		
	& BOQ				
2	Annexure-XII	DC – 2150 Beclomethasone	Few Prospective bidders have	Unit Size – 120 MDI	Unit size is amended as 200 MDI
	Clause 18(M)	Dipropionate IP 200mcg Inhaler	requested to revise the unit size to 200		
	& BOQ		MDI		
3	Annexure-XII	DC – 2151 Beclomethasone	One of the prospective bidders has	Unit Size – 120 MDI	The strength and unit size of the product is amended as
	Clause 18(M)	Dipropionate IP 300mcg Inhaler	requested to amend the strength of		follows:
	& BOQ		product to 100mcg and unit size to		Beclomethasone Dipropionate Inhaler IP 100mcg.
			200 MDI.		Each actuation delivers: Beclomethasone Dipropionate
					IP 100mcg
					suitable propellant qs.
					Unit Size: 200 MDI

Dated: 25.02.2022

4	Annexure-XII Clause 18(M) & BOQ	DC – 2155 Benidipine Hydrochloride Tablets IP 4mg	One of the prospective bidders has requested to amend the official compendium of the Drug and to amend the packing type of the drug to Alu-Alu	Generic name: Benidipine Hydrochloride Tablets IP 4mg Packing type - Strip	Generic name and packing type of the product is amended as follows: - Benidipine Hydrochloride Tablets 4mg Each Film coated tablet contains Benidipine Hydrochloride 4mg Packing type: Alu-Alu
5	Annexure-XII Clause 18(M) & BOQ	DC – 2156 Bilastine 20mg Montelukast 10mg Tablets	One of the Prospective bidders has requested to amend the specification to film coated-bilayered. Further, requested to amend the packing type of the drug to Alu-Alu	Each film coated tablet contains: Bilastine 20mg Montelukast Sodium eq. to Montelukast 10mg Bureau of India Packing type: Strips	Packing type: Alu-Alu The specification will remain same as per Annexure XII of tender document.
6	Annexure-XII Clause 18(M) & BOQ	DC – 2177 Lornoxicam 8mg and Paracetamol 500mg Tablets	One of the prospective bidders has requested to amend the strength of Paracetamol to 325mg	Each film coated tablet contains: Lornoxicam 8mg Paracetamol 500mg	The generic name and detailed specification are amended as follows: Lornoxicam 8mg and Paracetamol 325mg Tablets Each film coated tablet contains: Lornoxicam 8mg Paracetamol 325mg
7	Annexure-XII Clause 18(M) & BOQ	DC – 2188 Paroxetine Controlled Release Tablets 25mg	One of the Prospective bidders has requested to amend the packing type of the drug to Blister	Packing type: Strips	Tender condition prevails.

All other contents of tender document remain unaltered. Prospective bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment no.1 dated 25.02.2022.

Sd/-

DGM (Procurement & Quality)
Pharmaceuticals and Medical Devices Bureau of India (PMBI)
Ph. no. 011-49431811
e-mail: dgm.pnqc@janaushadhi.gov.in